Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review

Journal of Thoracic Oncology

Volumn 12, Issue 9, 2017, Pages 1344-1356

  Sacher, Adrian G ^a   Komatsubara, Kimberly M ^a   Oxnard, Geoffrey R ^b,c,d  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acquired resistance; EGFR; Liquid biopsy; NSCLC; Plasma genotyping; Targeted therapy

Indexed keywords

CISPLATIN; ERLOTINIB; GEFITINIB; GEMCITABINE; GENOMIC DNA; OSIMERTINIB; PHOSPHOTRANSFERASE INHIBITOR; ROCILETINIB;

EGFR GENE; GENOTYPING TECHNIQUE; HER2 GENE; HUMAN; MEDICAL DECISION MAKING; MET GENE; MONOTHERAPY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE; ONCOGENE K RAS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; GENETICS; LUNG TUMOR; PATHOLOGY; PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; GENOTYPING TECHNIQUES; HUMANS; LUNG NEOPLASMS;

EID: 85027511453     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2017.05.022     Document Type: Review

References (51)

1. Mandel, P., Metais, P., Les acides nucleiques du plasma sanguin chez l’ homme [The nucleic acids in blood plasma in humans]. C R Seances Soc Biol Fil 142 (1948), 241–243 [in French].
2. Bendich, A., Wilczok, T., Borenfreund, E., Circulating DNA as a possible factor in oncogenesis. Science 148 (1965), 374–376.
3. Leon, S.A., Shapiro, B., Sklaroff, D.M., Yaros, M.J., Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37 (1977), 646–650.
4. Stroun, M., Anker, P., Maurice, P., Lyautey, J., Lederrey, C., Beljanski, M., Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46 (1989), 318–322.
5. Jahr, S., Hentze, H., Englisch, S., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61 (2001), 1659–1665.
6. Stroun, M., Lyautey, J., Lederrey, C., Olson-Sand, A., Anker, P., About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 313 (2001), 139–142.
7. Sacher, A.G., Paweletz, C., Dahlberg, S.E., et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2 (2016), 1014–1022.
8. Diehl, F., Schmidt, K., Choti, M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 14 (2008), 985–990.
9. Gerlinger, M., Rowan, A.J., Horswell, S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366 (2012), 883–892.
10. Yates, L.R., Gerstung, M., Knappskog, S., et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 21 (2015), 751–759.
11. El Messaoudi, S., Rolet, F., Mouliere, F., Thierry, A.R., Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 424 (2013), 222–230.
12. Kimura, H., Kasahara, K., Kawaishi, M., et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12 (2006), 3915–3921.
13. Kuang, Y., Rogers, A., Yeap, B.Y., et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 15:8 (2009), 2630–2636.
14. Kim, H.R., Lee, S.Y., Hyun, D.S., et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res, 32, 2013, 50.
15. Mok, T.S., Wu, Y.L., Soo Lee, J., et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 21 (2015), 3196–3203.
16. Oxnard, G.R., Thress, K.S., Alden, R.S., et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 34 (2016), 3375–3382.
17. Oxnard, G.R., Paweletz, C.P., Kuang, Y., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20 (2014), 1698–1705.
18. Li BT, Janku F, Janne PA, et al. Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium [abstract]. Proceedings of the Annual Meeting of the American Association for Cancer Research 2016;New Orleans, LA. Philadelphia, PA: AACR; 2016:4342.
19. Lanman, R.B., Mortimer, S.A., Zill, O.A., et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PloS One, 10, 2015, e0140712.
20. Paweletz, C.P., Sacher, A.G., Raymond, C.K., et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res 22 (2016), 915–922.
21. Liu, B., Morrison, C.D., Johnson, C.S., et al. Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges. Oncotarget 4 (2013), 1868–1881.
22. US Food and Drug Administration. cobas EGFR Mutation Test v2. https://wwwfdagov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm504540htm Accessed February 26, 2017.
23. Jenkins S, Yang J, Ramalingam S, et al. Plasma ctDNA analysis for detection of EGFR T790M mutation in patients with EGFR mutation-positive advanced non-small cell lung cancer. Paper presented at: European Lung Cancer Conference 2016. April 1316, 2016; Geneva, Switzerland.
24. Reck, M., Hagiwara, K., Han, B., et al. ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study. J Thorac Oncol 11 (2016), 1682–1689.
25. Kim, S.T., Lee, W.S., Lanman, R.B., et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget 6 (2015), 40360–40369.
26. Bai, H., Mao, L., Wang, H.S., et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 27 (2009), 2653–2659.
27. Thompson, J.C., Yee, S.S., Troxel, A.B., et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res 22 (2016), 5772–5782.
28. Karlovich, C., Goldman, J.W., Sun, J.M., et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). Clin Cancer Res 22 (2016), 2386–2395.
29. Mok, T., Wu, Y.L., Lee, J.S., et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 21 (2015), 3196–3203.
30. Couraud, S., Vaca-Paniagua, F., Villar, S., et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res 20 (2014), 4613–4624.
31. Reckamp, K.L., Melnikova, V.O., Karlovich, C., et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol 11 (2016), 1690–1700.
32. Remon, J., Caramella, C., Jovelet, C., et al. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Ann Oncol 28 (2017), 784–790.
33. Karachaliou, N., Mayo-de las Casas, C., Queralt, C., et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol 1 (2015), 149–157.
34. Kimura, H., Suminoe, M., Kasahara, K., et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97 (2007), 778–784.
35. Goto, K., Ichinose, Y., Ohe, Y., et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 7 (2012), 115–121.
36. Douillard, J.Y., Ostoros, G., Cobo, M., et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 9 (2014), 1345–1353.
37. Newman, A.M., Bratman, S.V., To, J., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20 (2014), 548–554.
38. Weber, B., Meldgaard, P., Hager, H., et al. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer, 14, 2014, 294.
39. Yung, T.K., Chan, K.C., Mok, T.S., Tong, J., To, K.F., Lo, Y.M., Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15 (2009), 2076–2084.
40. Hu, C., Liu, X., Chen, Y., et al. Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. Oncol Rep 28 (2012), 1815–1821.
41. Brevet, M., Johnson, M.L., Azzoli, C.G., Ladanyi, M., Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 73 (2011), 96–102.
42. Wakelee H, Melnikova V, Karlovich C, et al. A highly sensitive next-generation sequencing platform for detection of NSCLC EGFR T790M mutation in urine and plasma. Paper presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer. December 4–7, 2016; Vienna, Austria.
43. Bettegowda, C., Sausen, M., Leary, R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med, 6, 2014, 224ra224.
44. Sacher, A., Dahlberg, S., Paweletz, C., et al. Prospective validation of rapid plasma genotyping as a sensitive and specific tool for guiding lung cancer care. JAMA Oncol 2 (2016), 1014–1022.
45. Mok, T.S., Wu, Y.L., Ahn, M.J., et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376 (2016), 629–640.
46. Friboulet, L., Li, N., Katayama, R., et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4 (2014), 662–673.
47. Ignatius Ou, S.H., Azada, M., Hsiang, D.J., et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 9 (2014), 549–553.
48. Katayama, R., Friboulet, L., Koike, S., et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 20 (2014), 5686–5696.
49. Johnson, A.C., Dô, P., Richard, N., et al. Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA. Lung Cancer 99 (2016), 38–40.
50. Sholl, L.M., Aisner, D.L., Varella-Garcia, M., et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience. J Thorac Oncol 10 (2015), 768–777.
51. Kahlert, C., Melo, S.A., Protopopov, A., et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 289 (2014), 3869–3875.